Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 7 (1998), Issue 2, Pages 111-114
http://dx.doi.org/10.1080/09629359891261

Levels of soluble Fas/APO-1 in patients with Behçet's disease

1Immunohistology Laboratory, Medicine University of Tunis, Pavillon VI, 9 rue Dr Z. Essafi , Tunis 1007, Tunisia
2Department of Respiratory Diseases, Pav II, Ariana, Tunisia
3Department of Rheumatology, Marsa Hospital, Tunisia

Copyright © 1998 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

The aim of this study was to quantify soluble Fas/APO1 (sFas/APO-1) protein in the serum of patients with Behcet's disease (BD) in active and inactive stages, compared with patients with systemic lupus erythematosus (SLE) and patients with rheumatoid arthritis (RA). Soluble Fas/APO-1 was quantified using a sandwich enzyme-linked immunosorbent assay. Increased serum sFas/APO-1 levels were observed in active BD, compared with inactive BD, RA patients and SLE patients. Increased serum sFas/APO-1 levels were correlated with the presence of neurologic manifestations or pulmonary involvement in active BD. In conclusion, increased levels of sFas/APO-1 occurred frequently and exclusively in active BD patients. Preliminary evidence suggested that elevated levels of sFas/APO-1 are associated with the clinical stage and clinical manifestations in BD.